Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy

Clinical Infectious Diseases

Volumn 55, Issue 10, 2012, Pages 1320-1328

  Schmader, K E ^a   Oxman, M N ^b   Levin, M J ^c   Johnson, G ^d   Zhang, J H ^d   Betts, R ^e   Morrison, V A ^f   Gelb, L ^g   Guatelli, J C ^b   Harbecke, R ^b   Pachucki, C ^g   Keay, S ^h   Menzies, B ^g,i   Griffin, M R ^j   Kauffman, C ^k   Marques, A ^k   Toney, J ^g   Keller, P M ^l   Li, X ^l   Chan, I S F ^l   Annunziato, P ^l   more..

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VA Cooperative Studies Program Coordinating Center   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MORBIDITY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; COHORT STUDIES; COST OF ILLNESS; DOUBLE-BLIND METHOD; EPIDEMIOLOGICAL MONITORING; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; MIDDLE AGED; PLACEBOS; UNITED STATES; VACCINATION;

EID: 84868013968     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis638     Document Type: Article

References (13)

1. Hope-Simpson RE. The nature of herpes zoster. Proc R Soc Med 1965; 58:9-20.
2. Oxman MN, Levin MJ, Johnson GR, et al. for the Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
3. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007; 23:490-6.
4. Oxman MN, Levin MJ, the Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197:S228-36.
5. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5:344-56.
6. Harbecke R, Oxman MN, Arnold BA, et al. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol 2009; 81:1310-22.
7. Chang MN, Guess HA, Heyse JF. Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994; 13:1807-14.
8. Guess HA, Lydick EG, Small RD, Miller LP. Exact binomial CIs for the relative risk in follow-up studies with sparsely stratified incidence density data. Amer J Epidemiol 1987; 125:340-7.
9. Guess HA, Thomas JE. A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data. Epidemiol 1990; 1:75-7.
10. Martin DO, Austin H. Exact estimates for a rate ratio. Epidemiol 1996; 7:29-33.
11. SAS Software. SAS, version 9.1-9.2 [computer program]. Cary, NC: SAS Institute, 2002-2008.
12. Cytel Software. StatXact, version 8.0 [computer program]. Cambridge, MA: Cytel, 2001.
13. Simberkoff MS, Arbeit RD, Johnson GR, et al. for the Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152: 545-54.